HOME
Leading the way to a cure

Scientific Advisory Board 2011

Mary K. (Peggy) Crow, M.D. (Chair)

Mary K. Crow, M.D.  - Scientific Advisory Board Chair

Mary K. Crow, MD, is the Benjamin M. Rosen Professor and Senior Scientist at Hospital for Special Surgery in New York and Professor of Medicine and Immunology at Weill Medical College of Cornell University. At Hospital for Special Surgery, Dr. Crow is Director of Rheumatology Research and Associate Chief of Rheumatology. In addition, she serves as Director of the Autoimmunity and Inflammation Research Program and as Co-Director of the Mary Kirkland Center for Lupus Research.

Dr. Crow earned an MD from Cornell University Medical College and completed an internship and internal medicine residency at New York Hospital in Manhattan. Her rheumatology clinical fellowship training was performed at Hospital for Special Surgery. She also served as a post-doctoral research fellow at Rockefeller University, where she was mentored by Dr. Henry Kunkel, a renowned immunologist who made significant contributions to the understanding of the mechanisms responsible for autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus.

Dr. Crow served as President of the American College of Rheumatology (2005-2006) and is very active in the rheumatology research community. Her own research has focused on the induction and regulation of human autoimmunity. She was among the first to characterize the functional properties of human dendritic cells and has studied self-reactive T cells in the prototype systemic autoimmune diseases, systemic lupus erythematous and rheumatoid arthritis. She continues to investigate the underlying triggers of autoimmune disease and the cellular and cytokine mediators of uncontrolled immune system activation in those disorders. She has published more than seventy scientific papers and has received research grant support from the NIH, the Arthritis Foundation, the Alliance for Lupus Research, the Lupus Research Institute, and the Mary Kirkland Center for Lupus Research. She was named an “Arthritis Hero” by the Arthritis Foundation in 2001.

Jeffrey Browning, PhD

Jeffrey Browing, PhD

Jeff Browning, PhD, is a Senior Director in the discovery Immunobiology group at Biogen Idec in Cambridge MA.  He received his PhD in biochemistry from the University of Wisconsin and did further studies in membrane biophysics and neurobiology at the University of Basel and at UCSF.  At Biogen Idec, he has studied various members of the TNF family of regulatory proteins and their application to medicine.  Browning and his group have been involved in the discovery of the Lymphotoxin, TWEAK and BAFF systems.  Lymphotoxin plays a key role in the organization of the immune system while BAFF is a potent survival factor for B cells.  TWEAK appears to be involved in organ remodeling including in the setting of kidney damage.  These discoveries have been translated now into multiple clinical trialsincluding active work on modulating the immune system in autoimmune disease with a Lymphotoxin inhibitor as well as harnessing the immune system to treat cancer.  His current focus is centered on making advances to facilitate the testing in patients of novel agents in lupus, Sjogren’s disease and progressive multiple sclerosis. 

Dennis A. Carson, MD

Dennis A. Carson, MD

Dennis A. Carson, M.D. is the Director, of the Moores Cancer Center, University of California San Diego (UCSD) School of Medicine. Carson earned his medical degree at Columbia University, completed his residency at UCSD, and received post-doctoral training at the Salk Institute, the National Institutes of Health and UCSD. He has published over 470 scientific papers, is an inventor on more than 70 issued U.S. patents, and has founded six biotechnology companies working in the oncology field. He is a member the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Carson is perhaps best known for developing 2-chlorodeoxyadenosine, or 2-CdA, for the treatment of hairy cell leukemia. This drug is the treatment of choice for this disease and has resulted in long term, complete remissions in about 75 percent of patients. He is convinced that novel partnerships between the public and private sectors are necessary to develop the next generation of anticancer treatments. As Cancer Center Director his priorities have been to develop strong, formalized relationships with the biotechnology and pharmaceutical communities to speed the translation of basic science discoveries, while maintaining academic freedom and economic incentives.

Robert L. Coffman, PhD

Dennis A. Carson, MD

Robert L. Coffman, PhD is the Vice President and Chief Scientific Officer of Dynavax Technologies in Berkeley, CA. Prior to joining Dynavax in 2000, Dr. Coffman was a founding member of the Scientific Staff of the DNAX Research Institute in Palo Alto, CA. Dr. Coffman has authored over 200 scientific publications and is a member of the National Academy of Sciences and the American Academy of Microbiology. He has devoted over 25 years to discovery of the pathways of immune regulation by T cells and cytokines. Dr. Coffman demonstrated that Interleukin-4 and Interferon- were the principal cytokines regulating IgE production in allergic responses. In 1986, with colleague Dr. Tim Mosmann, he defined the two principal subtypes of helper T cells, termed Th1 and Th2 cells, and demonstrated subsequently that all of the major features of allergic responses were coordinately regulated by the Th2 subset of T cells. Dr. Coffman demonstrated that Interleukin-4 mediated class switching to IgE by controlling rearrangement of immunoglobulin genes and discovered the parallel mechanism for the regulation of IgA responses by Transforming Growth Factor-B.
Dr .Coffman has defined mechanisms of T cell regulation in asthma and infectious and parasitic diseases and demonstrated of the central role regulatory CD4+ T cells in preventing inflammatory bowel disease. In his current position at Dynavax Technologies, Dr. Coffman is developing agonists and antagonists for Toll-like receptors, key recognition receptors in innate immunity. These compounds show promise as novel therapeutic agents for the treatment of allergic, infectious and autoimmune diseases.

Richard Flavell, PhD

Richard Flavell, PhD

Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1979 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) and Zurich (1972-73). Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences and the Institute of Medicine. Richard Flavell uses transgenic and gene-targeted mice to study T cell tolerance and activation in immunity and autoimmunity, apoptosis, and regulation of T cell differentiation.

Bevra Hahn

Richard Flavell, PhD

Bevra H. Hahn is Professor of Medicine, Vice-Chair of the Department of Medicine, and Chief of Rheumatology at the David Geffen School of Medicine, University of California Los Angeles, where she has been since 1983. A summa-cum-laude graduate of Ohio State University, Dr. Hahn received her medical degree from Johns Hopkins.She has been elected to Phi Beta Kappa, Alpha Omega Alpha, the American Society of Clinical Investigators, the Association of American Physicians and the Johns Hopkins Society of Scholars. She did an internship and residency in medicine in St. Louis at Barnes Hospital, Washington University. She is past-president of the American College of Rheumatology (ACR) and is currently a Master. She serves as the Chair of the NIH/NIAID Immune Tolerance Network Data and Safety Monitoring Board, and member of the Council of Councils, which is advisory to the Director of the NIH. Among her awards are the Dunlop-Dottridge Award of the Canadian Rheumatism Association for research in rheumatology, the Joseph Bunim Medal and prize of the American College of Rheumatology, the Holley Research prize in Rheumatology, the Southern California Arthritis Foundation's Klinenberg Medal for Arthritis Research, the Carol-Nachman International Award for Rheumatology Research, the first Evelyn V Hess Award of the Lupus Foundation of America for research in SLE, the 2007 ACR/REF Award of Distinction for Academic Mentoring, and the 2009 ACR Gold Medal. Dr. Hahn has authored more than 130 peer-reviewed research papers and over 40 book chapters or reviews as well as serving as co-editor of an influential textbook Dubois’ Lupus Erythematosus. She has served on the editorial boards of the Journal of Clinical Investigation and the Annals of Internal Medicine>. Her current research at the Laboratory for Lupus Research at UCLA includes investigations in immune tolerance, regulatory CD4+ and CD8+ T cells, genetics, accelerated atherosclerosis and treatment of systemic lupus. The laboratory is funded by grants from the National Institutes of Health, the Arthritis Foundation (Southern California Chapter), the American College of Rheumatology/Research Education Foundation, a Lupus Clinical Trials Center award, Rheuminations and private donors including Jeanne Rappaport.

Peter E. Lipsky, MD

Richard Flavell, PhD

Dr. Peter E. Lipsky received his medical degree from the New York University School of Medicine and spent much of his career at the University of Texas Medical Center, initially as Instructor in Internal Medicine and later as Professor of Internal Medicine and Microbiology.  Later appointments at the University of Texas Medical Center (1984-1999) included Director of the Harold C Simmons Arthritis Research Center, Co-Director of the Immunology Graduate Program at the Southwestern Graduate School of Biomedical Sciences, and Director of the Rheumatic Disease Division of the Department of Internal Medicine. Dr Lipsky was named the Harold C Simmons Professor in Arthritis Research in 1995, a position he held for 5 years.

Dr Lipsky's major research interests are B-cell biology, both in normal and autoimmune disease settings, and the generation of the immunoglobulin repertoire, and has authored over 500 articles. He serves on numerous journal editorial boards, and is the Co-Editor of Arthritis Research and Therapy and the Editor in Chief for Nature Clinical Practice Rheumatology. He has been awarded numerous prizes, including the Carol Nachman Prize in 2001, the Lee C. Howley Prize for Arthritis Research in 2002, the American College of Rheumatology's Distinguished Investigator Award in 2002, and the Japan Rheumatology Prize 2006.

Cox Terhorst, PhD

Chief, Division of Immunology, Harvard Medical School. More information coming soon.


1.5 million

people in the U.S. have Lupus.

90 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software